Aria Kashefi



Aria is a strategic advisor and legal counsel to emerging technology companies as well as venture capital and strategic investors. He combines his engineering background and years of legal experience to provide practical, business-focused advice to his clients as they continue to grow their business.

Aria Kashefi is a Partner in Orrick’s Technology Companies Group. Aria’s practice focuses on advising emerging technology companies and investors in a variety of transactional matters in the U.S. and internationally, including venture capital financings, exit transactions, technology licensing, corporate reorganization, governance and corporate and securities law.

  • Aria earned his B.A.Sc. (with distinction) in mechatronics, robotics and automation from the University of British Columbia in 2008 and received his J.D. from the University of Toronto in 2011. Prior to joining Orrick, Aria was an associate in the San Francisco office of another international law firm.

    • Nexa3D, in various transactions, including acquisition of Essentium, acquisition of Addifab ApS and $55 million+ convertible debt and equity financing rounds
    • Transcend, in its $40 million Series B financing led by Step Stone Group
    • Mitra Chem, in its $60 million Series B financing led by General Motors
    • Beacon Platform, in its $65 million Series C financing round led by Warburg Pincus
    • Opentrons, in its $200 million Series C financing round led by SoftBank Vision Fund II
    • D1 Capital Partners, in its lead investment in the $200 million Series B financing round of OneStream Software
    • Visa International, in various strategic investments, including in YellowPepper, ChargeAfter and Novopayment
    • Blackstone Life Sciences in its $350 million strategic investment in Reata Pharmaceuticals
    • SoftBank Vision Fund in its $225 million Series D+ investment in Klook
    • Ekso Bionics in various underwritten, registered direct and private placement offerings
    • Iota Biosciences, in its $340 million acquisition by Astellas Pharma
    • GigaGen, in its $80 million acquisition by Grifols